Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration-Reference-Cited by-同舟云学术

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Published:2013-06-27 Issue:2 Volume:109 Page:332-341
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bamias A,Tzannis K,Beuselinck B,Oudard S,Escudier B,Diosynopoulos D,Papazisis K,Lang H,Wolter P,de Guillebon E,Stravodimos K,Chrisofos M,Fountzilas G,Elaidi R-T,Dimopoulos M A,Bamia C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013341.pdf

Reference33 articles.

1. Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA (2010) Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 10: 45.

2. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22: 794–800.

3. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of Sorafenib, Sunitinib, and Temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917–930.

4. Choueiri T, Garcia J, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543–550.

5. Chow LQM, Eckhardt SG (2007) Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25: 884–896.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients;JU Open Plus;2024-04

2. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer;Kidney Cancer;2022-11-18

3. Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations;World Journal of Urology;2022-03-16

4. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma;Medicine;2021-08-06

5. Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma;Clinical Genitourinary Cancer;2019-06